MORRISVILLE, N.C. -- WEP Clinical (WEP), a full-service contract research organization (CRO), announced the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP’s global footprint and strengthens its ability to deliver end-to-end Phase I-IV clinical trial solutions across complex, rare, and specialized therapeutic areas.

Founded in 2000, Siron is headquartered in the Netherlands, with additional offices in Belgium and Germany, and clinical research professionals based across Europe and the Middle East. The company specializes in clinical operations, including project management, clinical monitoring, quality assurance, and regulatory submissions. Siron has supported more than 120 studies and has a strong track record in orphan diseases, pediatric research, and medical device trials.

Jaswinder Khera, WEP Founder and CEO, said:

“This acquisition represents a significant milestone in the evolution of our CRO services. By combining WEP’s global infrastructure with Siron’s deep operational expertise in complex and niche indications, we can offer sponsors seamless support from early-phase development through post-approval research. Our shared culture, values, and commitment to execution excellence make this an ideal strategic fit, and we look forward to accelerating innovation and impact together.”

Jan Balemans, Siron Founder and CEO, said:

“Joining WEP gives our clients access to expanded services and global reach, while preserving the flexible, hands-on approach they value. We share WEP’s commitment to quality, transparency, and patient-focused delivery, and together we will provide a more robust and scalable solution for biotech sponsors worldwide.”

Siron will be integrated into WEP’s Clinical Trials division, enhancing WEP’s existing capabilities across trial design, regulatory strategy, start-up, patient recruitment, study execution, and close-out. Clients will benefit from a larger pool of experienced CRAs, project managers, and operational leaders, alongside WEP’s broader treatment access and commercialization offerings.